In June-July 2025, Health Technology Wales (HTW) accomplished one full appraisal on implantable tibial neuromodulation devices for urinary incontinence. In addition, seven Med Tech-related Topic Exploration Reports were published in the e-health, diagnostic imaging, in-vitro diagnostics, neurology, and radiotherapy fields.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, van-Hove et al. analysed the carbon footprint of cataract surgery in England and the potential impact of adopting the NHS “Getting It Right First Time” (GIRFT) High Volume Low Complexity (HVLC) pathway.

On August 5, 2025, the Ministry of Labor, Health, Solidarity, and Families published the 2025 version of the List of Innovative Procedures Outside the Nomenclature (LAHN), which specifies tests funded under the innovative payment scheme for in-vitro diagnostics (RIHN). Tariffs for tests included in the LAHN were expected to decrease by 20% annually from January 1, 2025, except for those with a positive evaluation by the French National Authority for Health (HAS) in defined clinical indications. However, unlike previous edition, the 2025 LAHN does not specify tariffs. It introduces 14 new codes, which duplicate existing generic codes but are restricted to the clinical indications positively assessed by HAS. These new codes will be exempt from the annual tariff reduction.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, van Lieshout et al. examined how different stakeholders view the role of early health economic analyses (EHEA) in developing health innovations in the Netherlands.

In August 2025, the National Institute for Health and Care Excellence (NICE) announced two new projects within its Health Technology Assessment Innovation Laboratory (HTA Lab). The projects explore generative AI technologies in economic modelling and how AI can support and enhance NICE’s HTA processes through automation, predictive modeling, and reasoning systems.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Blanchard et al. explored the role of health technology assessment (HTA) in France beyond reimbursement and access to innovation.

In August 2025, the Common Catalog of Genetic and Genomic Tests of the National Health System in Spain was updated. Two sections with a total of 140 new genetic tests were introduced: one for bone diseases, including craniofacial anomalies, and another for kidney diseases and urogenital disorders. Furthermore, six new tests were added in pediatric oncohematology. Other changes concerned adult oncohaematology, hereditary metabolic, and mitochondrial diseases.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Eberle et al. explored whether the PICO elements (Population, Intervention, Comparator, Outcome) applied in EU Joint Clinical Assessments (JCAs) can be predicted across member states using publicly available data from national HTA bodies.

As of August 2025, the Centre for Assessment of Medical Technology in Örebro region in Sweden is working on health technology assessments in several areas, including in-vitro diagnostics, neuromodulation, and orthopedics.

On August 7, 2025, the UK National Screening Committee (UK NSC) launched a public consultation on its proposed recommendation to continue the in-service evaluation of newborn screening for severe combined immunodeficiency (SCID) in real-world NHS settings. Stakeholders are invited to submit comments by October 27, 2025.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Nunes et al. systematically reviewed 15 studies from seven countries on the implementation of decarbonisation actions in general practice.

On July 29, 2025, the French National Authority for Health (HAS) issued positive opinions on including targeted next-generation sequencing-based panels in certain clinical indications for patients with aminoacidopathy and acute leukaemia in the NABM Nomenclature for regular reimbursement. Currently, these tests are temporarily reimbursed within the innovative payment scheme (RIHN). These HAS assessments are performed by HAS as a part of the RIHN reform and ‘cleaning up’ the List of temporary covered tests.